<span item_type="fundamental" item_id="168b51ccd439cd8b9d1c7ac62fe61361" counter_id="ST/US/TIL" env="prod"></span><span item_type="announcement" item_id="582298440169823233" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 0.</p><p>EPS: As of FY2025 Q3, the actual value is USD -2.01, beating the estimate of USD -2.355.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -14.33 M.</p><p></p><h3>Financial Metrics Summary</h3><h4>Cash and Investments</h4><ul><li>As of September 30, 2025, Instil Bio, Inc. had cash, cash equivalents, restricted cash, marketable securities, and long-term investments totaling $83.4 million, compared to $115.1 million as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1789769/000178976925000092/q3-25er.htm"></span></li></ul><h4>Operating Expenses</h4><ul><li>In-process research and development expenses were $0 for the three months and $10.0 million for the nine months ended September 30, 2025, compared to $10.0 million for both periods in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1789769/000178976925000092/q3-25er.htm"></span></li><li>Research and development expenses were $9.1 million for the three months and $21.2 million for the nine months ended September 30, 2025, compared to $0.6 million and $10.7 million for the same periods in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1789769/000178976925000092/q3-25er.htm"></span></li><li>General and administrative expenses were $5.9 million for the three months and $21.2 million for the nine months ended September 30, 2025, compared to $10.7 million and $33.8 million for the same periods in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1789769/000178976925000092/q3-25er.htm"></span></li><li>Restructuring and impairment charges were $0 for the three months and $16.6 million for the nine months ended September 30, 2025, compared to $2.4 million and $7.1 million for the same periods in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1789769/000178976925000092/q3-25er.htm"></span></li></ul><h4>Net Loss</h4><ul><li>Net loss was $13.6 million for the three months and $63.2 million for the nine months ended September 30, 2025, compared to $23.0 million and $62.2 million for the same periods in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1789769/000178976925000092/q3-25er.htm"></span></li><li>Net loss per share, basic and diluted, was $2.01 for the three months and $9.53 for the nine months ended September 30, 2025, compared to $3.54 and $9.57 for the same periods in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1789769/000178976925000092/q3-25er.htm"></span></li></ul><h4>Non-GAAP Financial Measures</h4><ul><li>Non-GAAP net loss per share, basic and diluted, was $1.75 for the three months and $5.95 for the nine months ended September 30, 2025, compared to $2.55 and $6.51 for the same periods in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1789769/000178976925000092/q3-25er.htm"></span></li></ul><h3>Outlook / Guidance</h3><p>Instil Bio, Inc. expects its cash, cash equivalents, restricted cash, marketable securities, and long-term investments as of September 30, 2025, to fund its operating plan beyond 2026. The company acknowledges the risks and uncertainties associated with drug product development, regulatory approvals, and macroeconomic conditions that could impact its operations.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1789769/000178976925000092/q3-25er.htm"></span></p>

Instil Bio | 8-K: FY2025 Q3 Revenue: USD 0